To the best of our knowledge, the current study is the first to demonstrate that PCBP1 is downregulated in AML patients and accounts for approximately 72 % of newly diagnosed AML patients compared to healthy donors. This evidence concerns the gene PCBP1 and acute myeloid leukemia.